| The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions WH Shrank, T Hoang, SL Ettner, PA Glassman, K Nair, D DeLapp, ... Archives of internal medicine 166 (3), 332-337, 2006 | 445 | 2006 |
| Multiple sclerosis prevalence in the United States commercially insured population P Dilokthornsakul, RJ Valuck, KV Nair, JR Corboy, RR Allen, ... Neurology 86 (11), 1014-1021, 2016 | 317 | 2016 |
| Patient-level medication regimen complexity across populations with chronic disease AM Libby, DN Fish, PW Hosokawa, SA Linnebur, KR Metz, KV Nair, ... Clinical therapeutics 35 (4), 385-398. e1, 2013 | 216 | 2013 |
| Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates JD Campbell, V Ghushchyan, RB McQueen, S Cahoon-Metzger, ... Multiple sclerosis and related disorders 3 (2), 227-236, 2014 | 155 | 2014 |
| Understanding barriers to medication adherence in the hypertensive population by evaluating responses to a telephone survey KV Nair, DA Belletti, JJ Doyle, RR Allen, RB McQueen, JJ Saseen, ... Patient preference and adherence, 195-206, 2011 | 106 | 2011 |
| Description of antihypertensive use in patients with resistant hypertension prescribed four or more agents MR Hanselin, JJ Saseen, RR Allen, JC Marrs, KV Nair Hypertension 58 (6), 1008-1013, 2011 | 94 | 2011 |
| Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes RB McQueen, SL Ellis, JD Campbell, KV Nair, PW Sullivan Cost effectiveness and resource allocation 9, 1-8, 2011 | 80 | 2011 |
| Utilization characteristics of spinal interventions ZI Abbott, KV Nair, RR Allen, VR Akuthota The Spine Journal 12 (1), 35-43, 2012 | 76 | 2012 |
| Hospital-acquired pressure ulcers at academic medical centers in the United States, 2008–2012: tracking changes since the CMS nonpayment policy WV Padula, MBF Makic, HL Wald, JD Campbell, KV Nair, MK Mishra, ... The Joint Commission Journal on Quality and Patient Safety 41 (6), 257-263, 2015 | 74 | 2015 |
| Comparison of patient characteristics and gout-related health-care resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks JJ Saseen, N Agashivala, RR Allen, V Ghushchyan, AM Yadao, KV Nair Rheumatology 51 (11), 2004-2012, 2012 | 69 | 2012 |
| Effects of a 3-tier pharmacy benefit design on the prescription purchasing behavior of individuals with chronic disease KV Nair, P Wolfe, RJ Valuck, MM McCollum, JM Ganther, SJ Lewis Journal of Managed Care Pharmacy 9 (2), 123-133, 2003 | 66 | 2003 |
| Determining the cost of obesity and its common comorbidities from a commercial claims database WV Padula, RR Allen, KV Nair Clinical obesity 4 (1), 53-58, 2014 | 61 | 2014 |
| Diversity of Bacillus thuringiensis Strains From Qatar as Shown by Crystal Morphology, δ-Endotoxins and Cry Gene Content K Nair, R Al-Thani, D Al-Thani, F Al-Yafei, T Ahmed, S Jaoua Frontiers in microbiology 9, 708, 2018 | 60 | 2018 |
| Two decades of glatiramer acetate: From initial discovery to the current development of generics B Weinstock-Guttman, KV Nair, JL Glajch, TC Ganguly, D Kantor Journal of the Neurological Sciences 376, 255-259, 2017 | 56 | 2017 |
| Multiple sclerosis phenotypes as a continuum: the role of neurologic reserve TL Vollmer, KV Nair, IM Williams, E Alvarez Neurology: Clinical Practice 11 (4), 342-351, 2021 | 55 | 2021 |
| Effect of physician payment disclosure laws on prescribing G Pham-Kanter, GC Alexander, K Nair Archives of internal medicine 172 (10), 819-821, 2012 | 55 | 2012 |
| Economic burden of comorbid chronic kidney disease and diabetes RB McQueen, S Farahbakhshian, KF Bell, KV Nair, JJ Saseen Journal of medical economics 20 (6), 585-591, 2017 | 54 | 2017 |
| Adherence to statins in primary prevention: yearly adherence changes and outcomes JF Slejko, M Ho, HD Anderson, KV Nair, PW Sullivan, JD Campbell Journal of managed care pharmacy 20 (1), 51-57, 2014 | 52 | 2014 |
| Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: two-year experience B Vollmer, KV Nair, SH Sillau, J Corboy, T Vollmer, E Alvarez Multiple Sclerosis Journal–Experimental, Translational and Clinical 3 (3 …, 2017 | 50 | 2017 |
| Development of Glatopa®(glatiramer acetate): The first FDA-approved generic disease-modifying therapy for relapsing forms of multiple sclerosis C Bell, J Anderson, T Ganguly, J Prescott, I Capila, JC Lansing, ... Journal of pharmacy practice 31 (5), 481-488, 2018 | 48 | 2018 |
